Micron Technology said revenue quadrupled in the second quarter and forecast that rapid growth will continue on strong demand for its memory chips. The company's results beat Wall Street expectations on metrics such as sales, earnings per share and adjusted gross margin. The company also raised its forecast, and disclosed that it has struck 16 long-term deals to supply chips, a massive increase from the past. The stock climbed 15%, to $1204.23, in late trading.

ARS Pharmaceuticals said no commercial insurers had added its neffy nasal spray to their plans in the current insurance cycle. The company said neffy was added to Florida state Medicare coverage, but that there had been no commercial formulary additions or coverage decisions despite discussions with some payers stretching into mid-June. The company also cut its planned full-year cash-based operating expenses to around $248 million, citing cost discipline and the prioritization of commercial investments. Shares plunged 24%, to $8.05, in after-hours trading.

MillerKnoll notched higher sales in its latest quarter, driven by growth in its global retail and North America contract segments. However, incoming interim Chief Executive Officer Jeff Stutz said the company isn't pleased with the results. "I want to be clear that our financial performance is not where we want it to be," Stutz said during a call with analysts. The company is entering the current fiscal year with a few priority areas, including a focus on cost discipline and improving its balance sheet, he said. The stock fell 4.9%, to $16.40, in late trading.

Passage Bio signed an all-stock deal to merge with Remix Therapeutics, taking the latter company public. The merger plans come after the company initiated a strategic-review process in April, following the Food and Drug Administration saying it didn't support a single-arm trial design for Passage's dementia drug. Remix has secured commitments from investors for a $100 million private placement, expected to close after the merger, which is expected to fund the combined company's operations into 2028. Shares slid 17%, to $4.88, after market close.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 24, 2026 18:51 ET (22:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.